Medicare Enrolled
OIG Exclusion: cannot bill Medicare or Medicaid
This provider was excluded by the U.S. Office of Inspector General on
June 18, 2015
under section 1128a1
.
Currently active.
Verify on OIG.hhs.gov →
Dr. Eduardo Miranda, M.D.
Optician · Laredo, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Miranda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Miranda?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Miranda
Dr. Eduardo Miranda is an optician specialist in Laredo, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Miranda performed 64,808 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Miranda received a total of $29,885 from 95 pharmaceutical and/or device companies across 1496 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Miranda is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in TX
$29,885 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗64,808
Medicare services
Top 1% in TX for optician
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
35,700 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 14,205 | $43 | $95 |
| Denosumab injection (Prolia/Xgeva) | 5,521 | $18 | $32 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,996 | $0 | $1 |
| Anti-nausea injection (ondansetron/Zofran) | 1,222 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,090 | $1 | $5 |
| Iron dextran injection, 50 mg An injection containing 50 mg of iron dextran administered to the patient. |
659 | $13 | $25 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
509 | $60 | $152 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
475 | $93 | $219 |
| Heparin sodium injection, per 1000 units An injection of heparin sodium, a blood thinner, administered in units of 1000. |
362 | $0 | $5 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
318 | $99 | $305 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
303 | $22 | $62 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
302 | $6 | $34 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
188 | $48 | $154 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
147 | $11 | $50 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
121 | $22 | $68 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
118 | $49 | $140 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
117 | $1 | $1 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
97 | $10 | $37 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
88 | $117 | $321 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
75 | $26 | $72 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 72 | $129 | $525 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
59 | $16 | $45 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
28 | $20 | $117 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
20 | $126 | $400 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
16 | $93 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
56.6% high complexity
41.6% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$29,885
Total received (2018-2024)
Avg $4,269/year across 7 years
Top 7% in TX for optician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
95
Companies
1,496
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,528
2023
$4,870
2022
$4,416
2021
$5,025
2020
$3,160
2019
$3,648
2018
$3,238
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$1,215
PFIZER INC.
$434
AstraZeneca Pharmaceuticals LP
$355
Merck Sharp & Dohme LLC
$304
Genentech USA, Inc.
$229
Janssen Biotech, Inc.
$214
Celgene Corporation
$213
SEAGEN INC.
$199
Incyte Corporation
$131
Bayer Healthcare Pharmaceuticals Inc.
$104
Takeda Pharmaceuticals U.S.A., Inc.
$101
Regeneron Healthcare Solutions, Inc.
$101
Agios Pharmaceuticals, Inc.
$99
Eisai Inc.
$96
Bolton Medical Inc
$95
TerSera Therapeutics LLC
$89
Astellas Pharma US Inc
$86
GENZYME CORPORATION
$83
Karyopharm Therapeutics Inc.
$79
Sumitomo Pharma America, Inc.
$77
ADC Therapeutics America, Inc.
$77
Ipsen Biopharmaceuticals, Inc
$73
ARRAY BIOPHARMA INC
$71
GlaxoSmithKline, LLC.
$70
Gilead Sciences, Inc.
$66
Spectrum Pharmaceuticals Inc.
$54
Aveo Pharmaceuticals, Inc.
$51
ABBVIE INC.
$50
SOBI, INC
$50
E.R. Squibb & Sons, L.L.C.
$49
Alexion Pharmaceuticals, Inc.
$47
Lilly USA, LLC
$45
Genmab U.S., Inc.
$42
PUMA BIOTECHNOLOGY, INC.
$41
Stemline Therapeutics Inc.
$40
Rigel Pharmaceuticals, Inc.
$40
RECORDATI_RARE_DISEASES_INC.
$37
Blueprint Medicines Corporation
$37
Geron Corporation
$32
BeiGene USA, Inc.
$31
Tempus AI, Inc
$30
JAZZ PHARMACEUTICALS INC.
$27
Kite Pharma, Inc.
$27
Exelixis Inc.
$26
Deciphera Pharmaceuticals Inc.
$24
Mirati Therapeutics, Inc.
$23
ImmunoGen, Inc.
$22
Pharmacosmos Therapeutics Inc.
$21
Octapharma USA, Inc.
$20
Top 3 companies account for 36.3% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$3,030
PFIZER INC.
$2,454
Janssen Biotech, Inc.
$1,786
AstraZeneca Pharmaceuticals LP
$1,739
Astellas Pharma US Inc
$1,581
Amgen Inc.
$1,354
Seagen Inc.
$1,139
Incyte Corporation
$1,113
Merck Sharp & Dohme Corporation
$914
Genentech USA, Inc.
$873
E.R. Squibb & Sons, L.L.C.
$795
Merck Sharp & Dohme LLC
$779
Celgene Corporation
$764
GENZYME CORPORATION
$760
Rigel Pharmaceuticals, Inc.
$658
Eisai Inc.
$552
Karyopharm Therapeutics Inc.
$420
GlaxoSmithKline, LLC.
$379
Regeneron Healthcare Solutions, Inc.
$361
Gilead Sciences, Inc.
$353
Exelixis Inc.
$326
Boehringer Ingelheim Pharmaceuticals, Inc.
$294
EISAI INC.
$265
Takeda Pharmaceuticals U.S.A., Inc.
$252
Bayer Healthcare Pharmaceuticals Inc.
$246
Puma Biotechnology, Inc.
$239
ARRAY BIOPHARMA INC
$238
MorphoSys, US Inc.
$234
Lilly USA, LLC
$227
JAZZ PHARMACEUTICALS INC.
$219
ADC Therapeutics America, Inc.
$215
Ipsen Biopharmaceuticals, Inc
$215
Melinta Therapeutics, Inc.
$208
AVEO Pharmaceuticals, Inc.
$203
SEAGEN INC.
$199
Kite Pharma, Inc.
$191
Daiichi Sankyo Inc.
$180
BeiGene USA, Inc.
$174
Dova Pharmaceuticals
$172
Bayer HealthCare Pharmaceuticals Inc.
$170
AMAG Pharmaceuticals, Inc.
$170
PUMA BIOTECHNOLOGY, INC.
$144
Taiho Oncology, Inc.
$136
SOBI, INC
$134
EMD Serono, Inc.
$133
ABBVIE INC.
$131
Janssen Pharmaceuticals, Inc
$121
Epizyme, Inc.,
$116
Janssen Scientific Affairs, LLC
$107
Octapharma USA, Inc.
$107
Sumitomo Pharma America, Inc.
$104
Spectrum Pharmaceuticals Inc.
$102
Aveo Pharmaceuticals, Inc.
$102
Agios Pharmaceuticals, Inc.
$99
AbbVie, Inc.
$99
Bolton Medical Inc
$95
Pharmacosmos Therapeutics Inc.
$95
McKesson Specialty Care Distribution, LLC
$89
TerSera Therapeutics LLC
$89
Alexion Pharmaceuticals, Inc.
$88
Stemline Therapeutics Inc.
$85
Foundation Medicine, Inc.
$83
Verastem, Inc.
$80
Coherus Biosciences Inc.
$73
Blueprint Medicines Corporation
$71
Sobi, Inc
$68
Tactile Systems Technology Inc
$67
Myovant Sciences Inc.
$64
Deciphera Pharmaceuticals Inc.
$62
Seattle Genetics, Inc.
$61
Mirati Therapeutics, Inc.
$57
Pharmacyclics LLC, An AbbVie Company
$49
Genmab U.S., Inc.
$42
RECORDATI_RARE_DISEASES_INC.
$37
Melinta Therapeutics, LLC
$34
Kyowa Kirin, Inc.
$34
Geron Corporation
$32
Tempus AI, Inc
$30
Immunocore Limited
$25
Teleflex LLC
$25
TESARO, Inc.
$23
CTI BioPharma Corp.
$23
AbbVie Inc.
$22
ImmunoGen, Inc.
$22
Mylan Institutional Inc.
$21
Organon LLC
$21
Acceleron Pharma, Inc.
$21
TAIHO ONCOLOGY, INC.
$21
TG Therapeutics, Inc.
$18
Array BioPharma Inc.
$16
Clovis Oncology, Inc.
$15
R-Pharm US LLC
$15
Dendreon Pharmaceuticals LLC
$13
Acrotech Biopharma LLC
$12
Secura Bio, Inc.
$11
Top 3 companies account for 24.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · ALUNBRIG · ARROW · AYVAKIT · Alecensa · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Columvi · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELITEK · ELREXFIO · EMEND · EMPLICITI · ENHERTU · ERBITUX · ERLEADA · Enhertu · Epkinly · Erleada · FERAHEME · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FRUZAQLA · FULPHILA · Fabhalta · Farydak · Flexitouch Plus · Folotyn · GAVRETO · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · INVOKANA · Imbruvica · Ixempra · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · Monoferric · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · ORGOVYX · Ocrevus · Onivyde · Orbactiv · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · Prolia · QINLOCK · REBLOZYL · RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM · ROLVEDON · RYBREVANT · RYDAPT · RYTELO · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYLVANT · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · VARUBI · VENCLEXTA · VERZENIO · VOTRIENT · Vabomere · Vectibix · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Opticians in nearby ZIP areas
11
County median income
$62,506
Nearest hospital to ZIP centroid (approximate)
DOCTORS HOSPITAL OF LAREDO
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Miranda is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Miranda experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Miranda performed 35,700 iron infusion (feraheme) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Miranda receive payments from pharmaceutical companies?
Yes. Dr. Miranda received a total of $29,885 from 95 companies across 1,496 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Miranda's costs compare to other opticians in Laredo?
Dr. Miranda's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Miranda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Opticians in Laredo
Browse opticians in Laredo ranked by procedure volume and transparency data.
Highest volume
Top Opticians in TX
Opticians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Opticians in TX
Which TX opticians receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology